Journal article
Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform
Abstract
INTRODUCTION: In 2021, finerenone - a novel, selective nonsteroidal mineralocorticoid receptor antagonist - was approved in the USA to treat adults with chronic kidney disease (CKD) and type 2 diabetes (T2D). This study aimed to describe characteristics and short-term outcomes of patients prescribed finerenone since regulatory approval.
METHODS: This was a retrospective cohort study using claims and electronic health records data from the OM1 …
Authors
Kovesdy CP; Ebert N; Vizcaya D; Walsh M; Kosiborod MN; Layton JB; Ziemiecki R; Johannes CB; Pladevall-Vila M; Gee PO
Journal
Nephron, Vol. 149, No. 7, pp. 371–383
Publisher
Karger Publishers
Publication Date
2025
DOI
10.1159/000543923
ISSN
1660-8151